Hospital transfer after a breast cancer diagnosis: A population-based study in the Netherlands of the extent, predictive characteristics and its impact on time to treatment

E. Heeg* (Corresponding Author), K. Schreuder, P. E.R. Spronk, J. C. Oosterwijk, P. J. Marang-van de Mheen, S. Siesling, M. T.F.D.Vrancken Peeters,

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
2 Downloads (Pure)

Abstract

Purpose: Patients may transfer of hospital for clinical reasons but this may delay time to treatment. The purpose of this study is to provide insight in the extent of hospital transfer in breast cancer care; which type of patients transfer and what is the impact on time to treatment. Methods: We included 41,413 breast cancer patients registered in the Netherlands Cancer Registry between 2014 and 2016. We investigated transfer of hospital between diagnosis and first treatment being surgery or neoadjuvant chemotherapy (NAC). Co-variate adjusted characteristics predictive for hospital transfer were determined. To adjust for possible treatment by indication bias we used propensity score matching (PSM). Time to treatment in patients with and without hospital transfer was compared. Results: Among 41,413 patients, 8.5% of all patients transferred to another hospital between diagnosis and first treatment; 4.9% before primary surgery and 24.8% before NAC. Especially young (aged <40 years) patients and those who underwent a mastectomy with immediate breast reconstruction (IBR) were more likely to transfer. The association of mastectomy with IBR with hospital transfer remained when using PSM. Hospital transfer after diagnosis significantly prolonged time to treatment; breast-conserving surgery by 5 days, mastectomy by 7 days, mastectomy with IBR by 9 days and NAC by 1 day. Conclusions: While almost 5% of Dutch patients treated with primary surgery transfer hospital after diagnosis and up to 25% for patients treated with NAC, our findings suggest that especially those treated with primary surgery are at risk for additional treatment delay by hospital transfer.

Original languageEnglish
Pages (from-to)560-566
JournalEuropean journal of surgical oncology
Volume45
Issue number4
DOIs
Publication statusPublished - 1 Apr 2019

Fingerprint

Netherlands
Breast Neoplasms
Population
Mastectomy
Mammaplasty
Therapeutics
Drug Therapy
Patient Transfer
Propensity Score
Segmental Mastectomy
Registries

Keywords

  • Breast cancer
  • Discontinue of care
  • Hospital transfer
  • Treatment delay

Cite this

Heeg, E. ; Schreuder, K. ; Spronk, P. E.R. ; Oosterwijk, J. C. ; Marang-van de Mheen, P. J. ; Siesling, S. ; Peeters, M. T.F.D.Vrancken. / Hospital transfer after a breast cancer diagnosis : A population-based study in the Netherlands of the extent, predictive characteristics and its impact on time to treatment. In: European journal of surgical oncology. 2019 ; Vol. 45, No. 4. pp. 560-566.
@article{fc80f853c95b4bf9977115402b258cd0,
title = "Hospital transfer after a breast cancer diagnosis: A population-based study in the Netherlands of the extent, predictive characteristics and its impact on time to treatment",
abstract = "Purpose: Patients may transfer of hospital for clinical reasons but this may delay time to treatment. The purpose of this study is to provide insight in the extent of hospital transfer in breast cancer care; which type of patients transfer and what is the impact on time to treatment. Methods: We included 41,413 breast cancer patients registered in the Netherlands Cancer Registry between 2014 and 2016. We investigated transfer of hospital between diagnosis and first treatment being surgery or neoadjuvant chemotherapy (NAC). Co-variate adjusted characteristics predictive for hospital transfer were determined. To adjust for possible treatment by indication bias we used propensity score matching (PSM). Time to treatment in patients with and without hospital transfer was compared. Results: Among 41,413 patients, 8.5{\%} of all patients transferred to another hospital between diagnosis and first treatment; 4.9{\%} before primary surgery and 24.8{\%} before NAC. Especially young (aged <40 years) patients and those who underwent a mastectomy with immediate breast reconstruction (IBR) were more likely to transfer. The association of mastectomy with IBR with hospital transfer remained when using PSM. Hospital transfer after diagnosis significantly prolonged time to treatment; breast-conserving surgery by 5 days, mastectomy by 7 days, mastectomy with IBR by 9 days and NAC by 1 day. Conclusions: While almost 5{\%} of Dutch patients treated with primary surgery transfer hospital after diagnosis and up to 25{\%} for patients treated with NAC, our findings suggest that especially those treated with primary surgery are at risk for additional treatment delay by hospital transfer.",
keywords = "Breast cancer, Discontinue of care, Hospital transfer, Treatment delay",
author = "E. Heeg and K. Schreuder and Spronk, {P. E.R.} and Oosterwijk, {J. C.} and {Marang-van de Mheen}, {P. J.} and S. Siesling and Peeters, {M. T.F.D.Vrancken}",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.ejso.2018.12.017",
language = "English",
volume = "45",
pages = "560--566",
journal = "European journal of surgical oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "4",

}

Hospital transfer after a breast cancer diagnosis : A population-based study in the Netherlands of the extent, predictive characteristics and its impact on time to treatment. / Heeg, E. (Corresponding Author); Schreuder, K.; Spronk, P. E.R.; Oosterwijk, J. C.; Marang-van de Mheen, P. J.; Siesling, S.; Peeters, M. T.F.D.Vrancken.

In: European journal of surgical oncology, Vol. 45, No. 4, 01.04.2019, p. 560-566.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Hospital transfer after a breast cancer diagnosis

T2 - A population-based study in the Netherlands of the extent, predictive characteristics and its impact on time to treatment

AU - Heeg, E.

AU - Schreuder, K.

AU - Spronk, P. E.R.

AU - Oosterwijk, J. C.

AU - Marang-van de Mheen, P. J.

AU - Siesling, S.

AU - Peeters, M. T.F.D.Vrancken

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Purpose: Patients may transfer of hospital for clinical reasons but this may delay time to treatment. The purpose of this study is to provide insight in the extent of hospital transfer in breast cancer care; which type of patients transfer and what is the impact on time to treatment. Methods: We included 41,413 breast cancer patients registered in the Netherlands Cancer Registry between 2014 and 2016. We investigated transfer of hospital between diagnosis and first treatment being surgery or neoadjuvant chemotherapy (NAC). Co-variate adjusted characteristics predictive for hospital transfer were determined. To adjust for possible treatment by indication bias we used propensity score matching (PSM). Time to treatment in patients with and without hospital transfer was compared. Results: Among 41,413 patients, 8.5% of all patients transferred to another hospital between diagnosis and first treatment; 4.9% before primary surgery and 24.8% before NAC. Especially young (aged <40 years) patients and those who underwent a mastectomy with immediate breast reconstruction (IBR) were more likely to transfer. The association of mastectomy with IBR with hospital transfer remained when using PSM. Hospital transfer after diagnosis significantly prolonged time to treatment; breast-conserving surgery by 5 days, mastectomy by 7 days, mastectomy with IBR by 9 days and NAC by 1 day. Conclusions: While almost 5% of Dutch patients treated with primary surgery transfer hospital after diagnosis and up to 25% for patients treated with NAC, our findings suggest that especially those treated with primary surgery are at risk for additional treatment delay by hospital transfer.

AB - Purpose: Patients may transfer of hospital for clinical reasons but this may delay time to treatment. The purpose of this study is to provide insight in the extent of hospital transfer in breast cancer care; which type of patients transfer and what is the impact on time to treatment. Methods: We included 41,413 breast cancer patients registered in the Netherlands Cancer Registry between 2014 and 2016. We investigated transfer of hospital between diagnosis and first treatment being surgery or neoadjuvant chemotherapy (NAC). Co-variate adjusted characteristics predictive for hospital transfer were determined. To adjust for possible treatment by indication bias we used propensity score matching (PSM). Time to treatment in patients with and without hospital transfer was compared. Results: Among 41,413 patients, 8.5% of all patients transferred to another hospital between diagnosis and first treatment; 4.9% before primary surgery and 24.8% before NAC. Especially young (aged <40 years) patients and those who underwent a mastectomy with immediate breast reconstruction (IBR) were more likely to transfer. The association of mastectomy with IBR with hospital transfer remained when using PSM. Hospital transfer after diagnosis significantly prolonged time to treatment; breast-conserving surgery by 5 days, mastectomy by 7 days, mastectomy with IBR by 9 days and NAC by 1 day. Conclusions: While almost 5% of Dutch patients treated with primary surgery transfer hospital after diagnosis and up to 25% for patients treated with NAC, our findings suggest that especially those treated with primary surgery are at risk for additional treatment delay by hospital transfer.

KW - Breast cancer

KW - Discontinue of care

KW - Hospital transfer

KW - Treatment delay

UR - http://www.scopus.com/inward/record.url?scp=85059471032&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2018.12.017

DO - 10.1016/j.ejso.2018.12.017

M3 - Article

AN - SCOPUS:85059471032

VL - 45

SP - 560

EP - 566

JO - European journal of surgical oncology

JF - European journal of surgical oncology

SN - 0748-7983

IS - 4

ER -